Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Ou...
Main Authors: | Daniela Silva Moura, Serge Sultan, Sophie Georgin-Lavialle, Nathalie Pillet, François Montestruc, Paul Gineste, Stéphane Barete, Gandhi Damaj, Alain Moussy, Olivier Lortholary, Olivier Hermine |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22031830/pdf/?tool=EBI |
Similar Items
-
Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.
by: Daniela Silva Moura, et al.
Published: (2012-01-01) -
Clinical potential of midostaurin in advanced systemic mastocytosis
by: Chandesris MO, et al.
Published: (2017-05-01) -
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
by: Vermersch Patrick, et al.
Published: (2012-06-01) -
Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
by: Jesus S. Mora, et al.
Published: (2021-07-01) -
Case-control cohort study of patients' perceptions of disability in mastocytosis.
by: Olivier Hermine, et al.
Published: (2008-05-01)